Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Genedrive Share Price
  4. Genedrive Share Regulatory News
  5. Investor presentation

Pin to quick picksGenedrive Regulatory News (GDR)

Genedrive Information

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    0.025 (2.04%)
Bid:
1.20
Ask:
1.35
Spread: 0.15 (12.50%)
Market Cap: £20.07m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Investor presentation

10 Jun 2020 07:00

RNS Number : 4507P
Genedrive PLC
10 June 2020
 

genedrive plc

("genedrive" or the "Company")

 

Investor presentation

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that David Budd, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.

 

The event will be held on Friday, 12 June 2020 at 2pm. Please register your interest at https://voxmarkets.brand.live/c/genedrive-plc.

 

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently launched a high throughput SARS-CoV-2 assay and has a Genedrive® Point of Care version of the assay in development, both based on Genedrive® PCR chemistry.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFLFIRRFIAIII
891011121314151617
Date   Source Headline
8th Apr 20119:20 amRNSHolding(s) in Company
5th Apr 20112:34 pmRNSDirector/PDMR Shareholding
4th Apr 201112:41 pmRNSHolding(s) in Company
4th Apr 20119:35 amRNSHolding(s) in Company
29th Mar 20117:00 amRNSDirector/PDMR Shareholding
29th Mar 20117:00 amRNSInterim Results
28th Mar 20119:47 amRNSHolding(s) in Company
17th Mar 20119:23 amRNSRe Agreement - Replacement
17th Mar 20117:20 amRNSRe Agreement
28th Feb 20111:22 pmRNSInterim Results Announcement
18th Feb 20114:26 pmRNSHolding(s) in Company
5th Jan 201111:41 amRNSDirectors' Shareholdings and Report and Accounts
20th Dec 201011:36 amRNSAdviser - Change of Name
26th Nov 20103:48 pmRNSAGM results
3rd Nov 20107:00 amRNSCommercial Update
5th Oct 20107:00 amRNSFinal Results
4th Oct 201012:07 pmRNSDirector/PDMR Shareholding
10th Aug 201011:12 amRNSHolding(s) in Company
29th Jul 20107:00 amRNSPre close statement
23rd Jul 20101:50 pmRNSHolding(s) in Company
2nd Jul 201010:53 amRNSDirector/PDMR Shareholding
30th Apr 20109:42 amRNSHolding(s) in Company
1st Apr 20107:00 amRNSDirector's Shareholding Update
9th Mar 20107:00 amRNSChange of Adviser
9th Mar 20107:00 amRNSHalf Yearly Report
24th Feb 20109:55 amRNSHalf Yearly Report
4th Jan 20101:43 pmRNSDirector/PDMR Shareholding
9th Dec 20095:09 pmRNSHolding(s) in Company
2nd Dec 20097:00 amRNSResult of AGM
1st Dec 20095:34 pmRNSHolding(s) in Company
1st Dec 20095:33 pmRNSHolding(s) in Company
1st Dec 200911:11 amRNSHolding(s) in Company
30th Nov 20092:50 pmRNSHolding(s) in Company
20th Nov 20098:31 amRNSCash Placing
4th Nov 20092:38 pmRNSPosting of Annual Report and Accounts
23rd Oct 20099:57 amRNSHolding(s) in Company
21st Oct 20094:58 pmRNSHolding(s) in Company
16th Oct 20093:41 pmRNSHolding(s) in Company
12th Oct 20093:10 pmRNSDirector/PDMR Shareholding
6th Oct 20097:30 amRNSFinal Results
1st Oct 20097:00 amRNSDirector/PDMR Shareholding
18th Sep 20099:08 amRNSNotice of Preliminary Results
18th Aug 20093:29 pmRNSAdditional Listing
30th Jul 20097:30 amRNSPre-Close Trading Update
13th Jul 200910:46 amRNSHolding(s) in Company
13th Jul 200910:10 amRNSDirector/PDMR Shareholding
10th Jun 20099:50 amRNSHolding(s) in Company
30th Mar 20093:22 pmRNSDirector Declaration
17th Mar 20095:08 pmRNSAdditional Listing
11th Mar 20097:04 amRNSHalf Yearly Report
891011121314151617

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
NAS
North Atl.smlr
LSE
-0.26%
MPE
M P Evans
LSE
-3.10%
RTYS
Inv Russel 2000
LSE
1.12%
PSRE
Ivz Rafi Eur
LSE
0.44%
LQDA
iShares USD Corporate Bond UCITS ETF (Acc)
LSE
0.38%
Trending
BSFA
Bio-Sustainable Future Enterprises
LSE
0.00%
GEX
Georgina Energy
LSE
1.69%
PREM
Premier African Minerals
LSE
-16.00%
PANR
Pantheon Resources plc
LSE
31.07%
ALRT
Defence Holdings
LSE
0.00%